Is Truly Ra Medical Systems an Excellent Penny Stock to Buy?

The shares of commercial-stage medical tool maker Ra Medical Systems (RMED) have tumbled 92.7% in price over the past year due to investor issues bordering the business’s poor financial wellness. Also, provided the uncertainty surrounding the FDA’s approval of its DABRA catheter laser system, the concern ends up being, is the penny stock a safe bet now? Read on, allow’s learn.

Medical device firm Ra Medical Systems, Inc. (RMED – Get Ranking) in Carlsbad, Calif., is styles, develops, and markets excimer lasers to treat vascular diseases. The firm has actually made considerable development in essential campaigns, including its DABRA modern technology laser system and also atherectomy critical clinical research. However, the RMED stock quote has actually decreased 86.8% in cost over the past six months and 92.7% over the past year, showing investor concerns over its unsatisfactory income as well as incomes growth as well as the sale of its dermatology organization.

Closing yesterday’s session at $0.42, the stock is currently trading 95.7% listed below its 52-week high of $9.82, showing bearish view.

While the commercial-stage medical gadget business has filed a 510( k) application with the united state Food and Drug Administration (FDA) for its DABRA catheter, its commercialization leads stay unpredictable till its item gets authorization from the FDA. Additionally, the stock’s unfavorable productivity can make investors distressed.

Offering Shares

Last month, RMED priced an underwritten public offering of devices of its common stock, consisting of warrants to acquire up to 27.6 million shares of the ordinary shares and also pre-funded warrants to buy as much as 14.47 shares of common stock. The medical tool manufacturer anticipates about $12.1 million in gross profits from the offering.

Divestiture of Dermatology Business

Top 10 Stocks for 2022
In the third quarter, RMED finished the sale of its Pharos dermatology business for web proceeds of around $3.5 million. This was done as a part of the firm’s strategies to concentrate its sources on the market for medical tools to deal with outer artery condition (PAD). Nevertheless, the divestiture could negatively impact the medical tool manufacturer’s incomes as well as cost framework in the close to term and also cause RMED’s stock price to roll better.

Grim Success

The company’s trailing-12-month ROA and also cash from operations are negative 100.6% as well as $31.33 million, specifically. Additionally, its trailing-12-month gross profit margin, ROE and ROTC are unfavorable 18.9%, 115%, and 67%, specifically. And also its 0.12% property turnover ratio is 65.2% less than the 0.34% industry standard.

Faltering Financials
RMED’s web income from continuing procedures can be found in at $5,000 for the third quarter, finished Sept. 30, 2021, versus $68,000 in the third quarter of 2020. Its gross loss stood at $24,000 for the quarter, while running loss came in at $7.39 million. Furthermore, its net loss totaled up to $4.3 million, while its loss per share came in at $0.67. RMED reported a negative adjusted EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. And its total business expenses grew 2.1% year-over-year to $7.15 million during this period.

POWR Rankings Mirror Bleak Leads

RMED has a total D score, which converts to Market in our POWR Scores system. The POWR Scores are calculated by considering 118 distinct elements, with each variable weighted to an ideal degree.

Our exclusive rating system additionally evaluates each stock based on 8 distinctive classifications. RMED has an F quality for Top quality. This reflects the stock’s unfavorable ROA and cash flow from procedures.

The company has a D quality in Energy, constant with its price decline over the past 6 months. Also, it has an F quality for Stability, which remains in sync with its fairly high beta of 1.65.

Beyond the qualities I have actually highlighted, one can take a look at additional RMED scores for Sentiment, Growth, and also Value here. Amongst the 166 stocks in the D-rated Medical– Instruments & Equipment industry, RMED is rated # 119.


Analysts anticipate RMED’s EPS to remain unfavorable this year. While its initiatives to create DABRA catheters bode well, its negative profit margin as well as inadequate monetary strength might create its shares to decrease better. In addition, the uncertainty surrounding the regulative clearance and also commercialization of its DABRA laser system can elevate investors’ worries. So, we assume it is ideal prevented now.

Exactly How Does Ra Medical Systems (RMED) Stack Up Against its Peers?

While RMED has a general D (Sell) rating in our exclusive rating system, one might intend to take into consideration having a look at its sector peers, Fonar Company (FONR – Get Score), Electromed, Inc. (ELMD – Get Ranking), and also Abbott Laboratories (ABT – Obtain Score), having an A (Solid Buy) score.